Microarray-Based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Trinh, Xuan Bich ^a,b   Tjalma, Wiebren A A ^b   Dirix, Luc Y ^a   Vermeulen, Peter B ^a   Peeters, Dieter J ^a   Bachvarov, Dimcho ^c   Plante, Marie ^c   Berns, Els M ^d   Helleman, Jozien ^d   van Laere, Steven J ^a   van Dam, Peter A ^a  

^a Translational Cancer Research Unit   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c LAVAL UNIVERSITY   (Canada)

^d JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA CATENIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GAMMA INTERFERON; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROGESTERONE RECEPTOR; PROTEIN BRCA; PROTEIN KINASE B; PROTEIN P53; PROTEIN P63; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADVANCED SEROUS PAPILLARY OVARIAN CARCINOMA; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CANCER SURVIVAL; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PROGNOSIS; SCORING SYSTEM; CANCER INVASION; CELL LINE; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENETICS; ONCOGENE; OVARY TUMOR; PAPILLARY CARCINOMA; PATHOLOGY; SURVIVAL;

CARCINOMA, PAPILLARY; CELL LINE; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL ANALYSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79960742611     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022469     Document Type: Article

References (49)

1. Cannistra SA, (2004) Cancer of the ovary. N Engl J Med 351: 2519-2529.
2. Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI, (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 5165-5171.
3. Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, et al. (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25: 5180-5186.
4. Teoh DG, Secord AA, (2011) Antiangiogenic therapies in epithelial ovarian cancer. Cancer Control 18: 31-43.
5. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, et al. (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376: 245-251.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, et al. (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361: 123-134.
7. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, et al. (2010) Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28: 2512-2519.
8. Bild AH, Yao G, Chang JT, Wang Q, Potti A, et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357.
9. Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, et al. (2007) An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 25: 517-525.
10. Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, et al. (2010) A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A 107: 6994-6999.
11. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, et al. (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226.
12. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, et al. (2005) Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 102: 3738-3743.
13. Lauss M, Ringner M, Hoglund M, (2010) Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin Cancer Res 16: 4421-4433.
14. Mostertz W, Stevenson M, Acharya C, Chan I, Walters K, et al. (2010) Age- and sex-specific genomic profiles in non-small cell lung cancer. JAMA 303: 535-543.
15. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, et al. (2006) Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98: 262-272.
16. Tothill RW, Tinker AV, George J, Brown R, Fox SB, et al. (2008) Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14: 5198-5208.
17. Bachvarov D, L'esperance S, Popa I, Bachvarova M, Plante M, et al. (2006) Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol 29: 919-933.
18. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, et al. (2010) Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One 5: e9615.
19. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, et al. (2010) Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 28: 3555-3561.
20. Hu Z, Fan C, Livasy C, He X, Oh DS, et al. (2009) A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 7: 9.
21. Fattet S, Haberler C, Legoix P, Varlet P, Lellouch-Tubiana A, et al. (2009) Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. J Pathol 218: 86-94.
22. Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, et al. (2007) Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25: 3230-3237.
23. Loi S, Haibe-Kains B, Majjaj S, Lallemand F, Durbecq V, et al. (2010) PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci U S A 107: 10208-10213.
24. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, et al. (2008) Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 9: 239.
25. No authors listed (2010) Retraction. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol 25:4350-7, 2007. J Clin Oncol 28: 5229.
26. Bonnefoi H, Potti A, Delorenzi M, Mauriac L, Campone M, et al. (2011) Retraction-validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol 12: 116.
27. Potti A, Dressman HK, Bild A, Riedel RF, Chan G, et al. (2011) Retraction: Genomic signatures to guide the use of chemotherapeutics. Nat Med 17: 135.
28. Baggerly KA, Coombes KR, Neeley ES, (2008) Run batch effects potentially compromise the usefulness of genomic signatures for ovarian cancer. J Clin Oncol 26: 1186-1187.
29. Wirapati P, Sotiriou C, Kunkel S, Farmer P, Pradervand S, et al. (2008) Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 10: R65.
30. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, et al. (2002) Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol 100: 281-287.
31. Tetu B, Popa I, Bairati I, L'esperance S, Bachvarova M, et al. (2008) Immunohistochemical analysis of possible chemoresistance markers identified by micro-arrays on serous ovarian carcinomas. Mod Pathol 21: 1002-1010.
32. Hallstrom TC, Mori S, Nevins JR, (2008) An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell 13: 11-22.
33. Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, et al. (2006) Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer. Ann N Y Acad Sci 1091: 270-281.
34. Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, et al. (2007) Clinical relevance of E2F family members in ovarian cancer-an evaluation in a training set of 77 patients. Clin Cancer Res 13: 144-151.
35. Nusse R, (2008) Wnt signaling and stem cell control. Cell Res 18: 523-527.
36. Faleiro-Rodrigues C, Macedo-Pinto I, Pereira D, Lopes CS, (2004) Loss of beta-catenin is associated with poor survival in ovarian carcinomas. Int J Gynecol Pathol 23: 337-346.
37. Irving JA, Catasus L, Gallardo A, Bussaglia E, Romero M, et al. (2005) Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol 36: 605-619.
38. Rosen DG, Zhang Z, Chang B, Wang X, Lin E, et al. (2010) Low membranous expression of beta-catenin and high mitotic count predict poor prognosis in endometrioid carcinoma of the ovary. Mod Pathol 23: 113-122.
39. Stawerski P, Wagrowska-Danilewicz M, Stasikowska O, Gottwald L, Danilewicz M, (2008) Immunoexpression of beta-catenin-E-cadherin complex in primary serous ovarian tumors. Pol J Pathol 59: 27-32.
40. Voutilainen KA, Anttila MA, Sillanpaa SM, Ropponen KM, Saarikoski SV, et al. (2006) Prognostic significance of E-cadherin-catenin complex in epithelial ovarian cancer. J Clin Pathol 59: 460-467.
41. Hogdall EV, Christensen L, Hogdall CK, Blaakaer J, Gayther S, et al. (2007) Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study. Oncol Rep 18: 1051-1059.
42. Lee P, Rosen DG, Zhu C, Silva EG, Liu J, (2005) Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer. Gynecol Oncol 96: 671-677.
43. Tangjitgamol S, Manusirivithaya S, Khunnarong J, Jesadapatarakul S, Tanwanich S, (2009) Expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clinicopathologic study. Int J Gynecol Cancer 19: 620-627.
44. Yang XY, Xi MR, Yang KX, Yu H, (2009) Prognostic value of estrogen receptor and progesterone receptor status in young Chinese ovarian carcinoma patients. Gynecol Oncol 113: 99-104.
45. del Carmen MG, Fuller AF, Matulonis U, Horick NK, Goodman A, et al. (2003) Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 91: 596-602.
46. Papadimitriou CA, Markaki S, Siapkaras J, Vlachos G, Efstathiou E, et al. (2004) Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 66: 112-117.
47. Smyth JF, Gourley C, Walker G, MacKean MJ, Stevenson A, et al. (2007) Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients. Clin Cancer Res 13: 3617-3622.
48. Williams C, Simera I, Bryant A, (2010) Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev CD001034.
49. Williams CJ, (2001) Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev CD001034.